Brought to you by 
Geron intends to divest stem cell programs to BioTime; finalized
03 Jan 2022
Executive Summary
Geron Corp. (developing oncology therapeutics) signed a non-binding letter of intent to divest to stem cell technology firm BioTime Inc.’s newly established BioTime Acquisition Corp. (BAC) IP and assets covering its human embryonic stem cell programs.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Vaccines
-
Biotechnology
- Gene Therapy, Cell Therapy
- Immuno-Oncology
Deal Status
- Final
Deal Type
-
Alliance
- Includes Contract
- Includes Equity
- Includes Royalty or Profit Split Information
- Intra-Biotech Deal
- Product Purchase
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Geron intends to divest stem cell programs to BioTime; finalized
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice